Literature DB >> 22868293

Deterioration of fracture healing in the mouse model of NF1 long bone dysplasia.

T El Khassawna1, D Toben, M Kolanczyk, K Schmidt-Bleek, I Koennecke, H Schell, S Mundlos, G N Duda.   

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disease resulting from inactivating mutations in the gene encoding the protein neurofibromin. NF1 manifests as a heritable susceptibility to tumours of neural tissue mainly located in the skin (neurofibromas) and pigmented skin lesions. Besides these more common clinical manifestations, many NF1 patients (50%) have abnormalities of the skeleton. Long bones are often affected (usually the tibia) and the clinical signs range from bowing to spontaneous fractures and non-unions. Here we present the analysis of bone fracture healing in the Nf1(Prx1)-knock-out mouse, a model of NF1 long bone dysplasia. In line with previously reported cortical bone injury results, fracture healing was impaired in Nf1(Prx1) mice. We showed that the defective fracture healing in Nf1(Prx1) mice is characterized by diminished cartilaginous callus formation and a thickening of the periosteal bone. These changes are paralleled by fibrous tissue accumulation within the fracture site. We identify a population of fibrous tissue cells within the Nf1 deficient fracture as alpha-smooth muscle actin positive myofibroblasts. Additionally, histological and in-situ hybridization analysis reveal a direct contact of the fracture site with muscle fascia, suggesting a possible involvement of muscle derived cells in the fracture deterioration.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22868293     DOI: 10.1016/j.bone.2012.07.011

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

Review 1.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

2.  NF1 is a critical regulator of muscle development and metabolism.

Authors:  Kate Sullivan; Jad El-Hoss; Kate G R Quinlan; Nikita Deo; Fleur Garton; Jane T C Seto; Marie Gdalevitch; Nigel Turner; Gregory J Cooney; Mateusz Kolanczyk; Kathryn N North; David G Little; Aaron Schindeler
Journal:  Hum Mol Genet       Date:  2013-10-24       Impact factor: 6.150

3.  Short-term glucocorticoid treatment causes spinal osteoporosis in ovariectomized rats.

Authors:  W Böcker; T El Khassawna; N Bauer; K Brodsky; D Weisweiler; P Govindarajan; G Schlewitz; M Kampschulte; L Dürselen; U Thormann; G Szalay; R Schnettler; A C Langheinrich; C Heiss
Journal:  Eur Spine J       Date:  2014-07-31       Impact factor: 3.134

Review 4.  RASopathies: unraveling mechanisms with animal models.

Authors:  Granton A Jindal; Yogesh Goyal; Rebecca D Burdine; Katherine A Rauen; Stanislav Y Shvartsman
Journal:  Dis Model Mech       Date:  2015-08-01       Impact factor: 5.758

5.  T Lymphocytes Influence the Mineralization Process of Bone.

Authors:  Thaqif El Khassawna; Alessandro Serra; Christian H Bucher; Ansgar Petersen; Claudia Schlundt; Ireen Könnecke; Deeksha Malhan; Sebastian Wendler; Hanna Schell; Hans-Dieter Volk; Katharina Schmidt-Bleek; Georg N Duda
Journal:  Front Immunol       Date:  2017-05-24       Impact factor: 7.561

Review 6.  Multiscale Modeling of Bone Healing: Toward a Systems Biology Approach.

Authors:  Edoardo Borgiani; Georg N Duda; Sara Checa
Journal:  Front Physiol       Date:  2017-05-08       Impact factor: 4.566

7.  Effects of multi-deficiencies-diet on bone parameters of peripheral bone in ovariectomized mature rat.

Authors:  Thaqif El Khassawna; Wolfgang Böcker; Parameswari Govindarajan; Nathalie Schliefke; Britta Hürter; Marian Kampschulte; Gudrun Schlewitz; Volker Alt; Katrin Susanne Lips; Miriam Faulenbach; Henriette Möllmann; Daniel Zahner; Lutz Dürselen; Anita Ignatius; Natali Bauer; Sabine Wenisch; Alexander Claus Langheinrich; Reinhard Schnettler; Christian Heiss
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.